Ozempic And Hair Loss: Do GLP-1 Medications Cause Hair Loss?
GLP-1 medications have reshaped what’s possible in weight management. For millions of people, drugs like semaglutide and tirzepatide have delivered meaningful, measurable results. But as more patients report hair shedding months into treatment, a question keeps coming up in our consultations: “does Ozempic cause hair loss?”
The evidence suggests there is a connection. Ozempic (semaglutide) and similar drugs are linked to a higher risk of hair shedding, usually through indirect effects like rapid weight loss, metabolic stress, and nutrient deficiencies rather than direct damage to the hair follicle. People taking or considering semaglutide or tirzepatide should consult with a hair restoration specialist to prevent loss, restore their hair, or determine risk factors for hair loss.
Here’s what the current clinical research actually says, including how GLP-1-related shedding fits the pattern of telogen effluvium, when it tends to start and how long it may last, how it differs from other forms of hair loss, and when to seek evaluation or treatment.
Is There a Connection Between GLP-1 Medications and Hair Loss?
Yes. Several recent studies have identified an association between GLP-1 medications and increased reports of hair loss, particularly with semaglutide and tirzepatide, though the link between Ozempic and hair loss is not fully understood.
- A large study published in the Journal of the American Academy of Dermatology compared over half a million patients who started semaglutide or tirzepatide to a similar number of patients with matching age, health profiles, and other characteristics who did not take these medications. This side-by-side comparison found a significantly increased risk of new hair loss in the GLP-1 group, appearing as early as six months and continuing to climb by the one-year mark.
- A 2026 meta-analysis found a statistically higher risk of hair loss versus placebo in GLP-1 users.
- A review of the FDA’s public database of reported drug side effects found that hair loss was reported noticeably more often among people taking semaglutide or tirzepatide than would typically be expected, a signal that prompted researchers to investigate further.
- According to Wegovy’s prescribing information, hair loss was reported in 3.3% of patients treated with Wegovy 2.4 mg compared with 1% of patients receiving placebo.
Do GLP-1 Medications Damage The Hair Follicle Directly?
No, and this is the part that gets misunderstood most often. GLP-1 medications don’t appear to damage hair follicles directly. The mechanism is more indirect. Rapid, significant weight loss places metabolic stress on the body. In response, the body reallocates resources away from non-essential functions, and hair follicle activity is one of the first processes that is deprioritized.
In other words, GLP-1 medications don’t directly cause hair shedding at the follicle level. When shedding happens, the pattern is typically non-scarring and reversible.
Add to that the reduced caloric intake, lower appetite and food intake, potential protein deficits, and nutritional deficiencies in things like iron, zinc, B12, and vitamin D that can accompany these medications, all potential hair loss causes, and you have a combination of triggers well-established in the medical literature as drivers of a condition called telogen effluvium.
What Is Telogen Effluvium?
At any given time and under normal conditions, about 80% to 90% of scalp hair is in the active hair growth phase, while roughly 5% to 10% of hairs are in the resting phase (telogen), meaning they’re not actively growing and will eventually shed.
With telogen effluvium, a physiological stressor disrupts the hair growth cycle, and stress or hormonal changes can shift a much larger proportion of follicles out of growth and into that resting phase simultaneously. Two to three months later, those follicles begin to shed all at once, resulting in noticeable, diffuse thinning across the scalp.
This lines up with a broad review of the existing GLP-1 hair loss research, which found that the two most commonly reported types of hair loss were telogen effluvium and androgenetic alopecia (the well-known genetic, hormone-driven pattern of hair loss). Tirzepatide, which is associated with the greatest degree of weight loss of the GLP-1 medications, was the one most often linked specifically to telogen effluvium.
How Soon After Starting The Medication Does Shedding Start?
Shedding typically begins approximately two to three months after starting GLP-1 therapy, or after a significant dose increase. Most patients report peak shedding between three and six months. This delay is exactly why so many patients don’t initially connect their hair loss back to the medication.
Does It Ever Stop On Its Own?
Sometimes, yes. Ozempic-related hair loss is typically temporary. Once weight stabilizes, hair follicles usually return to their normal growth cycle. If nutritional intake is optimized and the underlying stressor is addressed, hair regrowth often begins and volume typically returns within six to twelve months, even after hair is lost. However, for some patients, shedding can persist beyond six months into what clinicians describe as chronic telogen effluvium. In others, the process may unmask or accelerate an underlying androgenetic alopecia that hadn’t yet become visible.
So Is It “Just Shedding,” Or Something More?
It can be either, which is exactly why an evaluation matters. Telogen effluvium and androgenetic alopecia can look similar in the early stages but require different approaches. When telogen effluvium is associated with nutritional deficiencies, appropriate dietary changes or supplements may help address the underlying trigger.
For androgenetic alopecia, on the other hand, treatments such as topical minoxidil may be recommended to help stimulate hair growth. Distinguishing between telogen effluvium and androgenetic alopecia, or recognizing when both are present, is a clinical judgment call that helps clinicians treat hair loss more effectively.
When Should I Get My Hair Loss Evaluated?
If you’re noticing increased hair shedding, finding more hair on your brush or pillow, or seeing excess hair in the shower, and you’ve started or increased a GLP-1 medication in the past several months, it’s worth getting evaluated rather than simply waiting for the shedding to stop.
Speak with your healthcare provider about your symptoms and whether factors such as thyroid function, iron levels, vitamin deficiencies, protein intake, or other nutritional factors should be evaluated through hair loss blood diagnostics panels. Reduced food intake while taking medications such as Ozempic can affect overall nutrition, which may contribute to hair shedding in some patients.
Most importantly, not all hair loss associated with GLP-1 medications is the same. What appears to be temporary shedding could be telogen effluvium, androgenetic alopecia, or a combination of both. Identifying the cause can help determine the appropriate next steps.
If you’ve noticed changes in your hair since starting Ozempic or another GLP-1 medication, don’t wait for the problem to become more noticeable. Schedule a consultation with Maxim Hair Restoration to have your hair loss evaluated by our doctors and clinicians. A trichological assessment can help identify what’s contributing to your shedding or thinning and determine which treatment options may be appropriate for you.
Maxim Hair Restoration is LegitScript Certified, reflecting recognized standards for transparency and patient safety.
References:
Herrera, H. O., & Bordeaux, J. S. (2026). Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology, 94(6), 1826–1827. https://doi.org/10.1016/j.jaad.2026.02.042
Cheng, P.-L., & Chang, H.-C. (2026). Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 237, 113333. https://doi.org/10.1016/j.diabres.2026.113333
Godfrey, H., Leibovit-Reiben, Z., Jedlowski, P., & Thiede, R. (2025). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology, 39(2), e153–e154. https://doi.org/10.1111/jdv.20197
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Malkud, S. (2015). Telogen effluvium: A review. Journal of Clinical and Diagnostic Research, 9(9), WE01–WE03. https://doi.org/10.7860/JCDR/2015/15219.6492
Gupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026). GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress, 109(2), 368504261444578. https://doi.org/10.1177/00368504261444578
